This section of the web-site contains information on medicines, advertising of which is not foreseen by the legislation. Information in this section is intended for reference only, has exclusively scientific and informative character and should not be treated as advertising information for a wide range of people. According to the current legislation, access to this information is granted to medical and pharmaceutical employees. Please confirm that you are a medical or pharmaceutical employee.
Products
Budenofalk®
Targeted delivery of high concentrations of the active agent to the site of inflammation is crucial when treating patients with inflammatory bowel diseases. This requirement is met by topical corticosteroid Budenofalk®1.
Budesonide, the active agent in Budenofalk® preparations, provides a strong topical effect on inflammatory processes, localized exclusively in the intestine and liver. For this reason, it is better tolerated than are conventional steroids1.
During Budenofalk® using, side effects are observed 2.4 times less often than when taking equivalent doses of systemic steroids of (prednisolone). Significantly more (2.4 times) patients achieve remission without the development of steroid side effects compared with prednisone. After the replacement of systemic corticosteroids by Budenofalk®, the number of steroid side effects are decreased in 3 times1.
The combination of powerful directional action and good tolerance allowed Budenofalk® to become a preparation of choice in the therapy of inflammatory bowel diseases, such as Crohn’s disease, ulcerative colitis and collagenous colitis. Budesonide (Budenofalk) is recommended by the European Organization for the Study of Crohn’s Disease and Ulcerative Colitis as a preferable therapy for Crohn’s disease of mild or moderate severity2.
Budenofalk® is a corticosteroid with a pronounced local anti-inflammatory effect for effective and safer* treatment of Crohn’s disease and collagenous colitis1,2.
Budesonide is also effective in chronic liver diseases. Encouraging results have been obtained in studies on the use of budesonide in chronic liver diseases, such as autoimmune hepatitis, primary biliary cirrhosis and overlap syndrome. So, with autoimmune hepatitis, Budenofalk® demonstrated significantly higher efficacy and better tolerability than prednisone1.
Due to the pronounced anti-inflammatory effect, the use of Budenofalk® in patients with autoimmune hepatitis allows achieving both clinical and biochemical remission3.
Budenofalk® – topical corticosteroid for effective and safer treatment* of Crohn’s disease, collagenous colitis and autoimmune hepatitis1-3.
* in comparison with systemic corticosteroids.
1. Budenofalk® in clinical practice – Freiburg: Dr. Falk Pharma GmbH, 2009.
2. Gomollon F. et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn’s and Colitis, 2017, 3-25.
3. Csepregi A. et al. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006; 12 (9): 1362-1366.